196
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Guillain-Barré Syndrome outbreak caused by ZIKA virus infection in French Polynesia

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          From October 2013 to April 2014, French Polynesia experienced the largest Zika virus (ZIKV) outbreak ever described at that time. During the same period, an increase in Guillain-Barré syndrome (GBS) was reported, suggesting a possible association between ZIKV and GBS.

          Patients and Methods

          A case-control study was performed to identify the role of ZIKV and dengue virus (DENV) infection in developing GBS. Cases were GBS patients diagnosed at the Centre Hospitalier de Polynésie Française during the outbreak period. Controls were age-, gender-, and residence-matched patients who presented at the hospital with a non-febrile illness (Control group 1 [CTR1]; n=98), and age-matched patients with acute ZIKV disease and no neurological symptoms (Control group 2 [CTR2]; n=70). Virological investigations included RT-PCR for ZIKV, and both microsphere immunofluorescent and seroneutralization assays for ZIKV and DENV. Anti-glycolipid reactivity was studied in GBS patients using both ELISA and combinatorial microarrays.

          Results

          Forty-two patients were diagnosed with GBS during the study period. Ninety-eight percent of GBS patients had anti-ZIKV IgM or IgG, and all had neutralizing antibodies against ZIKV compared to 55.7% with neutralizing antibodies in the CTR1 group (P<0.0001). Ninety-three percent of GBS patients had ZIKV IgM and 88% had experienced a transient illness in median six days before the onset of neurological symptoms, suggesting recent ZIKV infection. GBS patients had electrophysiological findings compatible with the acute motor axonal neuropathy (AMAN) type, and had rapid evolution of disease (median duration of the installation and plateau phases was 6 and 4 days, respectively). Twelve (29%) patients required respiratory assistance. No patients died. Anti-glycolipid antibody activity, notably against GA1, was found in 13 (31%) patients by ELISA and 19/41 (46%) by glycoarray at admission. The typical AMAN-associated anti-ganglioside antibodies were rarely present. There was no significant difference in past dengue history between GBS patients and the two control groups.

          Conclusion

          This is the first study providing evidence for ZIKV infection causing GBS. As ZIKV is spreading rapidly across the Americas, at risk countries need to prepare for adequate intensive care beds capacity for managing GBS patients.

          Related collections

          Author and article information

          Journal
          2985213R
          5470
          Lancet
          Lancet
          Lancet (London, England)
          0140-6736
          1474-547X
          20 April 2017
          02 March 2016
          09 April 2016
          25 May 2017
          : 387
          : 10027
          : 1531-1539
          Affiliations
          [1 ]Unit of Emerging Infectious Diseases, Institut Louis Malardé, Papeete, Tahiti, French Polynesia
          [2 ]Institut Pasteur, Emerging Diseases Epidemiology Unit, Paris, France
          [3 ]Service de réanimation polyvalente, Centre Hospitalier de Polynésie française, Tahiti, French Polynesia
          [4 ]Clinical laboratory, Centre Hospitalier de Polynésie française, Tahiti, French Polynesia
          [5 ]Institut Pasteur, Laboratory for Urgent Responses to Biological Threats, Paris, France
          [6 ]Unit Environment and Infectious Risks, Institut Pasteur, Paris, France
          [7 ]Service de neurologie, Centre Hospitalier de Polynésie française, 98713 Papeete, Tahiti, Polynésie française
          [8 ]Direction de la santé, Bureau de Veille Sanitaire, Papeete, French Polynesia
          [9 ]Service de santé des forces armées, French Polynesia
          [10 ]Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, UK
          [11 ]Department of Immunology, Laboratory of Immunochemistry & Autoimmunity, Pitié-Salpêtrière Hospital (AP-HP), Paris, France
          [12 ]UMR 134 PIMIT, University of Reunion island, INSERM U1187, CNRS 9192, IRD 249, La Reunion, 97491, France
          [13 ]Département de Neurophysiologie, Pitié-Salpêtrière Hospital (AP-HP), Paris, France
          [14 ]Conservatoire National des Arts et Métiers, Paris, France
          [15 ]Institut Pasteur, Centre for Global Health Research and Education, Paris, France
          Author notes
          Corresponding author: Prof Arnaud Fontanet, Emerging Diseases Epidemiology Unit, Institut Pasteur, 25, rue du Docteur Roux, Paris 75015, France, fontanet@ 123456pasteur.fr
          Article
          PMC5444521 PMC5444521 5444521 ems72373
          10.1016/S0140-6736(16)00562-6
          5444521
          26948433
          2c2fdf83-9965-4540-b304-130cb67a6929
          History
          Categories
          Article

          Comments

          Comment on this article